Huge bull call on BELLUS Health from Evercore implies +400% upside

Nov. 18, 2020 8:52 AM ETBELLUS Health Inc. (BLU), BLU:CABLUBy: Clark Schultz, SA News Editor1 Comment
  • BELLUS Health (NASDAQ:BLU) is on watch after Evercore ISI starts off coverage with an Outperform rating.
  • In a nutshell, analyst Josh Schimmer and team think the market dramatically underestimates the results of a key study.
  • "The P2 study of ‘5937 missed its primary endpoint, driving shares substantially lower and resulting in a valuation that leaves BLU off most investor radar screens. We believe investors acted in accordance with the negative headline associated with the study results and NOT the underlying data/scientific rationale which is why we are so positive compared to the street."
  • "But it turns out there was a surprisingly strong (and prespecified) signal within this 'failed' P2 trial – patients with more frequent cough at baseline had a clearer sign of benefit with ‘5937."
  • Evercore has a price target of $12 on BLU to rep more than 400% upside potential. The Evercore PT is almost double the average Wall Street price target as well.
  • BLU +7.11% premarket to $2.56.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.